Secretogranin 2 binds LILRB4 resulting in immunosuppression, UT Southwestern study suggests

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Dispatch Bio, a company aiming to engineer a universal immunotherapy treatment across solid tumors, announced its official launch.

July 25, 2025

Vol.51 No.29

In Brief

SITC Forward Fund announces 2025 fellowship recipients

The Society for Immunotherapy of Cancer Forward Fund announced the recipients of the 2025 SITC Fellowships.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.

July 18, 2025

Vol.51 No.28

Funding Opportunities

NCI, SITC immunotherapy fellowship calls for applications

NCI and the Society for Immunotherapy of Cancer are accepting applications for a one-year fellowship program beginning in July 2026.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.

July 11, 2025

Vol.51 No.27

Secretogranin 2 binds LILRB4 resulting in immunosuppression, UT Southwestern study suggests

YOU MAY BE INTERESTED IN

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

SITC Forward Fund announces 2025 fellowship recipients

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

NCI, SITC immunotherapy fellowship calls for applications

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Renew today!

Subscriber content

Never miss an issue!

Login